This study looks at a new drug called CC-92480 for people with Relapsed or Refractory Multiple Myeloma (RRMM). Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. When the usual treatments stop working, it's called "relapsed" or "refractory."

In this study, researchers want to know if CC-92480 is safe, how well it works, and how much should be used. It's combined with other treatments to see if it helps. Participants need to have tried other treatments and still have the disease. They also need to be in good physical shape and follow safety rules, like the Pregnancy Prevention Plan (PPP).

Some people can't join. For example, if they have certain other health problems or recently had COVID-19, they might not be able to participate.

• The study involves taking the drug and may require frequent visits to the clinic.
• Participants will be monitored for side effects and how their myeloma responds to treatment.
• Compensation for travel expenses may be provided, but participants should check with the study team.